File Download
There are no files associated with this item.
Supplementary
-
Citations:
- PubMed Central: 0
- Appears in Collections:
Article: Comparison Between Bare-Metal Stents, First-Generation Drug-Eluting Stents, and Bioresorbable Vascular Scaffolds
Title | Comparison Between Bare-Metal Stents, First-Generation Drug-Eluting Stents, and Bioresorbable Vascular Scaffolds |
---|---|
Authors | |
Keywords | Absorb Bare-metal stent Bioresorbable vascular scaffold; Drug-eluting stent Percutaneous coronary intervention |
Issue Date | 2021 |
Publisher | HMP Communications. The Journal's web site is located at http://www.invasivecardiology.com/jic/index.cfm |
Citation | Journal of invasive cardiology, 2021, v. 33 n. 6, p. e467-e473 How to Cite? |
Abstract | Background: The long-term clinical outcomes after bioresorbable vascular scaffold (BVS) implantation have been extensively compared with second-generation drug-eluting stent (DES) implantation, but not with bare-metal stent (BMS) or first-generation DES options.
Objective: To compare the major adverse cardiovascular event (MACE) rates after implantation of BVS, first-generation DES, and BMS.
Methods: This was a single-center observational study based on a registry of percutaneous coronary intervention (PCI). The primary endpoint was MACE at 3 years, defined as a composite endpoint of death, non-fatal myocardial infarction, and target-vessel revascularization.
Results: A total of 170 consecutive patients who underwent PCI with implantation of everolimus-eluting BVS (Absorb; Abbott Cardiovascular) between 2014 and 2017 were compared with a control group of 622 patients implanted with BMS and 604 patients implanted with first-generation DES from 2001 to 2005. In adjusted analysis, DES had a lower risk of MACE at 3 years compared with BMS (adjusted odds ratio [OR], 0.58; 95% confidence interval [CI], 0.41-0.81; P<.01), while BVS had a similar risk of MACE compared with BMS (adjusted OR, 0.91; 95% CI, 0.55-1.52; P=.72). When compared with DES, BVS had a similar risk of MACE (adjusted OR, 1.45; 95% CI, 0.83-2.53; P=.19).
Conclusions: In patients with BVS implantation, the risk of the composite outcome of MACE at 3 years was not significantly different when compared with patients with BMS or first-generation DES implantation. |
Description | Open Access Journal |
Persistent Identifier | http://hdl.handle.net/10722/306708 |
ISSN | 2023 Impact Factor: 1.6 2023 SCImago Journal Rankings: 0.468 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ng, KYA | - |
dc.contributor.author | Yeung, PNP | - |
dc.contributor.author | Siu, DCW | - |
dc.contributor.author | Jim, MH | - |
dc.date.accessioned | 2021-10-22T07:38:27Z | - |
dc.date.available | 2021-10-22T07:38:27Z | - |
dc.date.issued | 2021 | - |
dc.identifier.citation | Journal of invasive cardiology, 2021, v. 33 n. 6, p. e467-e473 | - |
dc.identifier.issn | 1557-2501 | - |
dc.identifier.uri | http://hdl.handle.net/10722/306708 | - |
dc.description | Open Access Journal | - |
dc.description.abstract | Background: The long-term clinical outcomes after bioresorbable vascular scaffold (BVS) implantation have been extensively compared with second-generation drug-eluting stent (DES) implantation, but not with bare-metal stent (BMS) or first-generation DES options. Objective: To compare the major adverse cardiovascular event (MACE) rates after implantation of BVS, first-generation DES, and BMS. Methods: This was a single-center observational study based on a registry of percutaneous coronary intervention (PCI). The primary endpoint was MACE at 3 years, defined as a composite endpoint of death, non-fatal myocardial infarction, and target-vessel revascularization. Results: A total of 170 consecutive patients who underwent PCI with implantation of everolimus-eluting BVS (Absorb; Abbott Cardiovascular) between 2014 and 2017 were compared with a control group of 622 patients implanted with BMS and 604 patients implanted with first-generation DES from 2001 to 2005. In adjusted analysis, DES had a lower risk of MACE at 3 years compared with BMS (adjusted odds ratio [OR], 0.58; 95% confidence interval [CI], 0.41-0.81; P<.01), while BVS had a similar risk of MACE compared with BMS (adjusted OR, 0.91; 95% CI, 0.55-1.52; P=.72). When compared with DES, BVS had a similar risk of MACE (adjusted OR, 1.45; 95% CI, 0.83-2.53; P=.19). Conclusions: In patients with BVS implantation, the risk of the composite outcome of MACE at 3 years was not significantly different when compared with patients with BMS or first-generation DES implantation. | - |
dc.language | eng | - |
dc.publisher | HMP Communications. The Journal's web site is located at http://www.invasivecardiology.com/jic/index.cfm | - |
dc.relation.ispartof | Journal of invasive cardiology | - |
dc.rights | Creative Commons: Attribution 3.0 Hong Kong License | - |
dc.subject | Absorb | - |
dc.subject | Bare-metal stent | - |
dc.subject | Bioresorbable vascular scaffold; | - |
dc.subject | Drug-eluting stent | - |
dc.subject | Percutaneous coronary intervention | - |
dc.title | Comparison Between Bare-Metal Stents, First-Generation Drug-Eluting Stents, and Bioresorbable Vascular Scaffolds | - |
dc.type | Article | - |
dc.identifier.email | Yeung, PNP: pyeungng@hku.hk | - |
dc.identifier.email | Siu, DCW: cwdsiu@hkucc.hku.hk | - |
dc.identifier.authority | Yeung, PNP=rp02517 | - |
dc.identifier.authority | Siu, DCW=rp00534 | - |
dc.identifier.pmid | 34077386 | - |
dc.identifier.hkuros | 328489 | - |
dc.identifier.volume | 33 | - |
dc.identifier.issue | 6 | - |
dc.identifier.spage | e467 | - |
dc.identifier.epage | e473 | - |
dc.publisher.place | United States | - |